Fatih Demırkan

5.2k total citations · 1 hit paper
82 papers, 926 citations indexed

About

Fatih Demırkan is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Fatih Demırkan has authored 82 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 36 papers in Genetics and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Fatih Demırkan's work include Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (22 papers) and Chronic Myeloid Leukemia Treatments (14 papers). Fatih Demırkan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (22 papers) and Chronic Myeloid Leukemia Treatments (14 papers). Fatih Demırkan collaborates with scholars based in Türkiye, United States and Spain. Fatih Demırkan's co-authors include Mehmet Ali Özcan, Carol Moreno, Bülent Ündar, Alessandra Tedeschi, Martin Šimkovič, John G. Gribben, Richard Greil, Devinder Gill, Bertrand Anz and Emily Hsu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fatih Demırkan

71 papers receiving 909 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Fatih Demırkan

Since Specialization

Citations

This map shows the geographic impact of Fatih Demırkan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatih Demırkan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatih Demırkan more than expected).

Fields of papers citing papers by Fatih Demırkan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatih Demırkan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatih Demırkan. The network helps show where Fatih Demırkan may publish in the future.

Co-authorship network of co-authors of Fatih Demırkan

This figure shows the co-authorship network connecting the top 25 collaborators of Fatih Demırkan. A scholar is included among the top collaborators of Fatih Demırkan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatih Demırkan. Fatih Demırkan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study 2025 ·Haematologica ·Muhıt Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, (unknown), Ying Chen, Alejandra Nieto, Fatih Demırkan, Pau Montesinos, Fevzi Altuntaş	1
2	Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA) 2022 ·Transfusion and Apheresis Science ·Leylagül Kaynar, Emre Tekgündüz, İlknur Kozanoğlu, (unknown), (unknown), Fahir Özkalemkaş, Fatih Demırkan	3
3	Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): the Turkish hematology research and education group (ThREG)-TMA02 study 2022 ·Transfusion and Apheresis Science ·(unknown), Emre Tekgündüz, Ramazan Esen, Mehmet Birhan Yılmaz, Volkan Karakuş, Filiz Vural, (unknown), İsmet Aydoğdu, Leylagül Kaynar, Hakan Göker, (unknown), Orhan Ayyıldız, Fatih Demırkan	0
4	Evaluation of using fresh frozen plasma for patients with cirrhosis at a tertiary healthcare center in Turkey: Strict transfusion policies are essential 2021 ·Transfusion and Apheresis Science ·(unknown), (unknown), Göksel Bengı, İnci Alacacıoğlu, Güner Hayri Özsan, Fatih Demırkan	1
5	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study 2021 ·Annals of Hematology ·Richard Greil, Alessandra Tedeschi, Carol Moreno, Bertrand Anz, Loree Larratt, Martin Šimkovič, Devinder Gill, John G. Gribben, Ian W. Flinn, Zhengyuan Wang, Leo W.K. Cheung, Aaron Nguyen, Cathy Zhou, Lori Styles, Fatih Demırkan	9
6	Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion? 2021 ·Molecular Cytogenetics ·(unknown), (unknown), Hava Üsküdar Teke, (unknown), (unknown), Zafer Gülbaş, Fatih Demırkan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sevilhan Artan, Olga Meltem Akay	8
7	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial breakdown → 2018 ·The Lancet Oncology ·Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Šimkovič, Olga Samoilova, Jan Novák, Dina Ben‐Yehuda, Владимир Стругов, Devinder Gill, John G. Gribben, Emily Hsu, Chih‐Jian Lih, Cathy Zhou, Fong Clow, Danelle F. James, Lori Styles, Ian W. Flinn	380
8	Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment? 2018 ·Turkish Journal of Hematology ·(unknown), (unknown), (unknown), Ömür Gökmen Sevindik, Faize Yüksel, (unknown), Mehmet Ali Özcan, Fatih Demırkan, Bülent Ündar, İnci Alacacıoğlu, Hayri Özsan	3
9	What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? 2018 ·Transfusion and Apheresis Science ·(unknown), Fatih Demırkan	2
10	IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY 2016 ·Haematologica ·Graeme Fraser, Paula Cramer, Fatih Demırkan, (unknown), Sebastian Grosicki, Ann Janssens, Jiřı́ Mayer, Marie‐Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, André Goy, Abraham Avigdor, (unknown), Charles E. Phelps, Michelle Mahler, Mariya Salman, Angela Howes, Michael Hallek	4
11	Kronik Lenfositik Lösemi Hastalarının Genel Klinik Değerlendirilmesi 2012 ·(unknown), (unknown), (unknown), (unknown), Güner Hayri Özsan, Fatih Demırkan, Bülent Ündar, Mehmet Ali Özcan	1
12	Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient 2011 ·Blood Coagulation & Fibrinolysis ·(unknown), (unknown), (unknown), (unknown), Mehmet Ali Özcan, Fatih Demırkan, Güner Hayri Özsan, (unknown)	5
13	The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: A single institution experience from Turkey 2007 ·Leukemia & lymphoma ·Fatih Demırkan, İnci Alacacıoğlu, (unknown), Hayri Özsan, Barış Akıncı, (unknown), Tuğba Yavuzşen, (unknown), Bülent Ündar	10
14	Bortezomib-Induced Skin Lesion 2006 ·Acta Haematologica ·Mehmet Ali Özcan, (unknown), (unknown), Banu Lebe, (unknown), (unknown), Fatih Demırkan, Güner Hayri Özsan, (unknown)	3
15	Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines 2005 ·Leukemia & lymphoma ·Filiz Vural, Mehmet Ali Özcan, Güner Hayri Özsan, Halil Ateş, Fatih Demırkan, (unknown), Bülent Ündar	5
16	Bilateral primary orbital non-Hodgkin's lymphoma in a patient with scleroderma: A case report 2005 ·Leukemia & lymphoma ·(unknown), Mehmet Ali Özcan, (unknown), Ayşe Nur Demiral, (unknown), Fatih Demırkan, Güner Hayri Özsan, Ali Osman Saatçi, Bülent Ündar	4
17	Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders 2003 ·Thrombosis Research ·Mehmet Ali Özcan, Abdurrahman Çömlekçi, Fatih Demırkan, Faize Yüksel, İ̇smail Sarı, Tevfik Demir, Güner Hayri Özsan, (unknown), Sena Yeşil, Bülent Ündar	19
18	Effect of Granulocyte-Colony-Stimulating Factor on Serum Lactate Dehydrogenase Levels and Isoenzymes in a Rabbit Model 2002 ·Acta Haematologica ·(unknown), (unknown), Fatih Demırkan, (unknown), Mehmet Ali Özcan, (unknown), (unknown)	1
19	Hemophagocytic Syndrome Associated with Inappropiate Secretion of Antidiuretic Hormone in Lymphoma and Acute Myeloblastic Leukemia: Report of Two Cases 2001 ·Leukemia & lymphoma ·Fatih Demırkan, Filiz Vural, (unknown), Mehmet Ali Özcan, Şermin Özkal, Bülent Ündar	12
20	Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease 2001 ·American Journal of Hematology ·Mesut Akarsu, Fatih Demırkan, (unknown), Fatoş Önen, Faize Yüksel, Síbel A. Özkan, Bülent Ündar	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact